

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
9 September 2005 (09.09.2005)

PCT

(10) International Publication Number  
WO 2005/082344 A1

(51) International Patent Classification: A61K 31/136

(21) International Application Number:  
PCT/US2005/005754

(22) International Filing Date: 23 February 2005 (23.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/547,130 24 February 2004 (24.02.2004) US

(71) Applicant (for all designated States except US):  
SMITHKLINE BEECHAM CORPORATION  
[US/US], One Franklin Place, P.O. Box 7929, Philadel-  
phia, Pennsylvania 19101 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GOODWIN,  
Bryan, James [GB/US]; GlaxoSmithKline, Five Moore  
Drive, Post Office Box 13398, Research Triangle Park,  
North Carolina 27709 (US); STEWART, Eugene, Lee  
[US/US]; GlaxoSmithKline, Five Moore Drive, Post

Office Box 13398, Research Triangle Park, North Car-  
olina 27709 (US); BROWN, Peter, Jonathan [GB/US];  
GlaxoSmithKline, Five Moore Drive, Post Office Box  
13398, Research Triangle Park, North Carolina 27709  
(US); DELERIVE, Philippe [FR/FR]; GlaxoSmithKline,  
Centre de Recherches, Z.A. de Courtaboeuf, 25 Avenue du  
Quebec, F-91940 Les Ulis (FR).


(74) Agents: DADSWELL, Charles, E. et al.; GlaxoSmithK-  
line, Five Moore Drive, Post Office Box 13398, Research  
Triangle Park, North Carolina 27709 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ,  
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,  
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

4 Title: LRH1 ACTIVATORS AS MEDICAMENTS



: Methods or prevention or treatment of diseases or conditions caused by low plasma apoA-I levels, the use of LRH1  
ch methods and methods for the identification of compounds useful in such treatment.